Start-Up Quarterly Statistics, Q3 2010

Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million in Q3 2010, a 29% jump from the previous quarter and a 50% increase from Q3 2009. A total of eight start-up acquisitions closed in Q3, quite a jump from the first two quarters of 2010. The third quarter saw 14 biopharma alliances covering a wide range of therapeutic categories, the most popular indication being cancer.

In the third quarter of 2010, biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million, a 29% jump from the previous quarter and a 50% increase from the third quarter of 2009. ( See Exhibit 1.) Biopharma companies did well in Q3, bringing in $446 million, or 30% more than the previous quarter. Not so for in vitro diagnostics start-ups, which raised just $99 million, 39% less than they did in Q2. Device companies were the most successful at generating more funds compared with Q2 – with a 130% hike. (This spike was mostly due to Devicor Medical Products Inc.'s equity financing, which accounted for 66% of Q3's device total.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.